ACCELERON INITIATES TRIAL OF ACE-011
Acceleron Pharma has initiated a Phase I clinical trial of ACE-011, a novel treatment for bone loss disease, particularly osteoporosis. ACE-011 is the first regenerative therapeutic to enter human clinical trials from Acceleron's scientific platform that utilizes the body's own naturally-occurring growth factors.
Acceleron is conducting the Phase I study in healthy post-menopausal women. The study is a randomized, placebo-controlled, a single ascending dose study designed to evaluate safety, tolerability, and pharmacology properties of ACE-011.